argenx NV ADR (ARGX)vsOrchestra BioMed Holdings Inc. (OBIO)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
OBIO
Orchestra BioMed Holdings Inc.
$4.66
-2.10%
HEALTHCARE · Cap: $278.56M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 12553% more annual revenue ($4.24B vs $33.48M). ARGX leads profitability with a 30.5% profit margin vs -1.6%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
OBIO
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Intrinsic value data unavailable for OBIO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Revenue surging 121.2% year-over-year
Conservative balance sheet, low leverage
Strong operational efficiency at 21.8%
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -109.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : OBIO
The strongest argument for OBIO centers on Revenue Growth, Debt/Equity, Operating Margin. Revenue growth of 121.2% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : OBIO
The primary concerns for OBIO are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ARGX profiles as a growth stock while OBIO is a hypergrowth play — different risk/reward profiles.
OBIO carries more volatility with a beta of 0.59 — expect wider price swings.
OBIO is growing revenue faster at 121.2% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 32/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Orchestra BioMed Holdings Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New Hope, Pennsylvania.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?